Patent EP-2653869-A2 (EP)
Inventor: MOUTHON LUC
IPC: G01N33/564
Filed: 2010-02-25
Abstract: In vitro process for detecting vasculitis in a subject, or a risk of developing vasculitis, comprises determining presence and/or quantity of at least one antiendothelial cell antibody directed against an antigen comprising e.g. vinculin, far upstream element-binding protein 2, caldesmon, 78kDa protein precursor regulated by glucose, heat shock cognate 71 kDa protein, and mitochondrial precursor of the Stress-70 protein, in a biological sample from a patient, where the presence of at least one antibody is indicative of a vasculitis or risk of developing a vasculitis. In vitro process for detecting vasculitis in a subject, or a risk of developing vasculitis, comprises: determining the presence and/or quantity of at least one antiendothelial cell antibody directed against an antigen comprising vinculin, far upstream element-binding protein 2 (FUbp2), caldesmon, 78kDa protein precursor regulated by glucose, heat shock cognate 71 kDa protein, mitochondrial precursor of the stress-70 protein, lamin-A/C, heterogeneous nuclear ribonucleoprotein K, T-complex protein 1 subunit epsilon, mitochondrial precursor of 60-kDa heat shock protein, protein disulfide-isomerase A1 precursor, protein disulfide-isomerase A3 precursor, T-complex protein 1 theta subunit, T-complex protein 1 beta subunit, mitochondrial precursor of ATP synthase alpha subunit, heterogeneous nuclear ribonucleoprotein H, tubulin beta chain, fructose- bisphosphate aldolase A, mitochondrial precursor of ATP synthase alpha subunit, calumenin precursor, reticulocalbin-3 26S proteasome non-ATPase regulatory subunit 4, inorganic pyrophosphatase, Annexin A5, 14-3-3 protein epsilon, 6-phosphogluconolactonase, galectin-1, mitochondrial precursor of succinyl-CoA A transferase 1, heterogeneous nuclear D0 ribonucleoprotein, 26S protease regulatory subunit 7, heme oxygenase 2, histone H2B type F-S, proteasome subunit alpha type-5, proteasome subunit beta type-2, protein 4 associated with cytoskeleton, Uroporphyrinogen decarboxylase, adenine phosphoribosyltransferase, profilin-1, plastine-3, growth factor receptor-bound protein 2, heterogeneous nuclear ribonucleoprotein L, reticulocalbin-1 precursor, SerpinB9, mitochondrial precursor of the isocitrate dehydrogenase alpha subunit [NAD], guanine monophosphate synthase [hydrolyzing the glutamine], T-complex protein 1 subunit zeta, cofilin-1, mitochondrial precursor of aconitate hydratase, mitochondria inner membrane protein, heterogeneous nuclear ribonucleoprotein K, mitochondrial precursor of elongation factor Tu, alcohol dehydrogenase [NADP+], sialic acid synthase, S-formylglutathione hydrolase, guanine nucleotide-binding protein subunit beta-2-like 1, purine nucleoside phosphorylase, prohibitin, mitochondria precursor of C1q-binding protein, ATPase of the transitional endoplasmic reticulum and nucleoside diphosphate kinase A, in a biological sample from a patient, where the presence of at least one antibody is indicative of a vasculitis or risk of developing a vasculitis. Independent claims are included for: (1) an in vitro process for prognosis or monitoring of vasculitis, comprising determining the presence and/or quantity of at least one the antibody in a biological sample from a patient, at different times, where the increase of the amount of the antibody is indicative of aggravation of vasculitis; and (2) in vitro process for evaluating the effectiveness of a treatment against a vasculitis comprising determining the presence and/or quantity of at least the antibody in a biological sample of a patient, before, during or after treatment, where the decrease of the amount of the antibody is indicative of improvement of vasculitis. ACTIVITY : Vasotropic; Antiinflammatory; Antiallergic; Immunosuppressive; Vasotropic. MECHANISM OF ACTION : None given.